News
SDZXF
81.25
NaN%
--
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?
Seeking Alpha · 16h ago
Jefferies Keeps Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 2d ago
Sandoz expands biosimilar pipeline with major Henlius collaboration
TipRanks · 3d ago
Sandoz price target raised to CHF 80 from CHF 75 at JPMorgan
TipRanks · 08/10 19:10
Sandoz Group Ltd (SDZXF) Gets a Hold from RBC Capital
TipRanks · 08/06 06:56
Barclays Remains a Buy on Sandoz Group Ltd (SDZXF)
TipRanks · 08/06 06:55
Goldman Sachs Reaffirms Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 08/06 05:25
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Seeking Alpha · 08/05 20:05
S&P Futures Gain on Hopes for U.S.-Iran Deal; SpaceX and AMD Sink After Earnings
Barchart · 08/05 05:46
Sandoz H1 2026 profits surge as biosimilars drive growth and strategy
TipRanks · 08/05 05:32
Sandoz in $450M settlement over 43 US states' antitrust claims
Seeking Alpha · 08/03 15:58
Sandoz takes steps to resolve U.S. generic medicine pricing litigation
TipRanks · 08/03 10:45
Sandoz seals major U.S. settlements in generic drug antitrust saga
TipRanks · 08/03 05:33
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Seeking Alpha · 07/31 21:15
Sandoz confirms Brazil regulatory approval for new semaglutide treatment option
TipRanks · 07/29 10:15
Sandoz wins Brazilian approval for new semaglutide diabetes treatment
TipRanks · 07/29 10:02
Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins
Seeking Alpha · 07/25 00:22
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
Seeking Alpha · 07/16 19:53
Sandoz Reshapes Leadership to Seize Generics Growth Wave
TipRanks · 07/15 05:32
RBC Capital Sticks to Its Hold Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 07/09 06:16
More
Webull provides a variety of real-time SDZXF stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZXF
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.